Olema Pharmaceuticals (OLMA) Price & Analysis

Compare

776 Followers

OLMA Stock Chart & Stats

$8.19

$0.55(10.50%)

At close: Jan 08 4:00 PM EST

$8.19

$0.55(10.50%)

Day’s Range― - ―

52-Week Range$2.86 - $13.51

Previous CloseN/A

Volume1.27M

Average Volume (3M)1.41M

Market Cap

$533.29M

Enterprise Value$7.06M

Total Cash (Recent Filing)$361.91M

Total Debt (Recent Filing)$1.75M

Price to Earnings (P/E)―

Beta1.77

Next Earnings

Nov 11, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.51

Shares Outstanding68,634,330

10 Day Avg. Volume1,793,192

30 Day Avg. Volume1,405,975

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.01

Enterprise Value/Revenue19.40

Enterprise Value/Gross Profit-172.22

Enterprise Value/Ebitda-0.05

Forecast

1Y Price Target

$23.60

Price Target Upside188.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessOlema announced impressive updated data from the Phase 1b/2 trial of palazestrant and ribociclib in patients with ER+/HER2- metastatic breast cancer.

Competitive AdvantagePalazestrant has the most interesting monotherapy and CDK combination data of all competitors.

Investment OpportunityThere is a favorable setup for Olema's stock based on the totality of known data, providing a potential investment opportunity.

Bears Say

Adverse EventsThe most common adverse events were mainly of low grade, and less severe adverse events were observed at the Phase 3 dose of 90 mg.

Competitor PerformanceThe phase 3 evERA study of a competitor's treatment showed a disappointing hazard ratio for progression-free survival, which may increase caution in related future studies.

Market ValuationOLMA shares are materially undervalued in the refractory setting alone.

Olema Pharmaceuticals News

JPMorgan healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss the recently held ESMO 2025 (European Society for Medical Oncology) with Olema (OLMA) on an...

6s ago

OLMA

Midday Fly By: AWS hit by outage, Kering sells beauty unit

The major averages were broadly higher near noon as markets opened with a cautiously optimistic tone amid strong...

3d ago

Morning Movers: Cleveland-Cliffs surges following earnings report

Stock futures in the U.S. are edging higher as markets are opening with a cautiously optimistic tone amid...

3d ago

CLF

COO

Oppenheimer remains bullish on Olema despite ‘Jekyll and Hyde kinda ESMO’

Oppenheimer analyst Matthew Biegler notes Olema Pharmaceuticals (OLMA) delivered stellar second-line data in combination with ribociclib at ESMO,...

3d ago

CHRO

OLMA

Olema announces updated data on Phase 1b/2 study of palazestrant, ribociclib

Olema Pharmaceuticals announced updated data from the Phase 1b/2 study of palazestrant in combination with ribociclib in patients...

4d ago

OLMA

Olema Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Olema Oncology (OLMA) with a Buy rating and $20 price target The firm sees...

15d ago

OLMA

Olema Pharmaceuticals Reports Positive Phase 1b/2 Trial Results

An update from Olema Pharmaceuticals ( ($OLMA) ) is now available. On October 18, 2025, Olema Pharmaceuticals announced...

3d ago

OLMA

Promising Potential of Olema Pharmaceuticals’ Palazestrant in ER+/HER- Metastatic Breast Cancer Treatment: An Analyst’s Buy Recommendation

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on OLMA stock, giving a Buy rating today....

3d ago

OLMA

Promising Efficacy and Safety of Olema Pharmaceuticals’ Palazestrant in Metastatic Breast Cancer Trials Supports Buy Rating

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals, retaining the price target of...

3d ago

OLMA

Promising Potential of Olema Pharmaceuticals’ Palazestrant in ESR1 Patient Treatment Drives Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Olema Pharmaceuticals. The associated price target...

27d ago

OLMA

Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA

Oppenheimer notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY) evERA trial was...

1M ago

CHRO

OLMA

Oppenheimer reiterates Buy on Olema, sees evERA readthrough to persevERA

Oppenheimer analyst Matthew Biegler notes that Olema (OLMA) shares are up today, likely on news that Roche’s (RHHBY)...

1M ago

CHRO

OLMA

Olema Pharmaceuticals: Strategic Positioning and Promising Outlook in the Oral SERD Market

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals, with...

1M ago

OLMA

Oppenheimer says Olema collaboration with Pfizer could lead to bidding war

Oppenheimer analyst Matthew Biegler says the firm had a chance to speak with Olema Oncology (OLMA) management after...

2M ago

NVS

PFE

OLMA FAQ

What was Olema Pharmaceuticals, Inc.’s price range in the past 12 months?

Olema Pharmaceuticals, Inc. lowest stock price was $2.86 and its highest was $13.51 in the past 12 months.

What is Olema Pharmaceuticals, Inc.’s market cap?

Olema Pharmaceuticals, Inc.’s market cap is $533.29M.

When is Olema Pharmaceuticals, Inc.’s upcoming earnings report date?

Olema Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 19 days.

How were Olema Pharmaceuticals, Inc.’s earnings last quarter?

Olema Pharmaceuticals, Inc. released its earnings results on Aug 11, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.134.

Is Olema Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Olema Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Olema Pharmaceuticals, Inc. pay dividends?

Olema Pharmaceuticals, Inc. does not currently pay dividends.

What is Olema Pharmaceuticals, Inc.’s EPS estimate?

Olema Pharmaceuticals, Inc.’s EPS estimate is -0.48.

How many shares outstanding does Olema Pharmaceuticals, Inc. have?

Olema Pharmaceuticals, Inc. has 68,634,330 shares outstanding.

What happened to Olema Pharmaceuticals, Inc.’s price movement after its last earnings report?

Olema Pharmaceuticals, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 16.193%.

Which hedge fund is a major shareholder of Olema Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in OLMA

Olema Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-49.72%

Trailing 12-Months

Asset Growth

50.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.

Olema Pharmaceuticals (OLMA) Earnings & Revenues

Historic Earnings Reports

OLMA Stock 12 Month Forecast

Average Price Target

$23.60

▲(188.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","29":"$29","8.75":"$8.75","15.5":"$15.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8.75,15.5,22.25,29],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.344615384615384,13.649230769230769,14.953846153846154,16.25846153846154,17.563076923076924,18.86769230769231,20.17230769230769,21.47692307692308,22.78153846153846,24.08615384615385,25.39076923076923,26.695384615384615,{"y":28,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,12.006153846153845,12.972307692307691,13.938461538461539,14.904615384615385,15.87076923076923,16.836923076923078,17.803076923076922,18.76923076923077,19.735384615384618,20.701538461538462,21.66769230769231,22.633846153846157,{"y":23.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.04,11.72923076923077,12.418461538461537,13.107692307692307,13.796923076923076,14.486153846153845,15.175384615384615,15.864615384615384,16.553846153846152,17.243076923076924,17.932307692307692,18.621538461538464,19.310769230769232,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >